Farrell, good points on the Data Monitoring Committee (DMC) which is documented in your clinicaltrials.gov attachment. As you mentioned the DMC’s interim analysis is a safety review. Brilacidin’s safety profile has been proven in multiple human trials so IMO this interim analysis will be a formality. With 120 patients the 15%-20% mark would be 18-24 patients so we could see the decision by the DMC to extend dosing from 3 days to 5 days at any time now.

IMO Brilacidin will kill most if not all of the CV19 virus in the first 3 doses but a 4th and 5th dose will make it easier to do an apples to apples comparison of Brilacidin treated patients vs the SOC patients using repurposed antiviral drugs (likely Remdesivir in the U.S. and Favipiravir in Russia) getting the same 5 day treatment.

Remdesivir and Favipiravir are both ineffective as antivirals after the early stages of CV19. Brilacidin could shine as it could continue to dramatically reduce the viral load as it kills the virus so the extra dosing on days 4 & 5 could be a huge differentiator for Brilacidin. Also Severe CV19 patients are most affected by inflammatory responses and cytokine storm issues. Brilacidin’s immuno/anti-inflammatory properties could also significantly differentiate it vs the baseline SOC. If the Brilacidin treated Severe patients are walking out of the hospital on day 6 and their unfortunate SOC counterparts are being intubated, it will be obvious to all that Brilacidin is a unique and powerful CV19 treatment.

The next few IPIX PR’s will be exciting to watch as they unfold. The world will soon be hearing about a CV19 therapeutic breakthrough that only a small group of investors have been aware of.